BioLargo (BioLargo) Retained Earnings : $-147.10 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is BioLargo Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BioLargo's retained earnings for the quarter that ended in Dec. 2023 was $-147.10 Mil.

BioLargo's quarterly retained earnings declined from Jun. 2023 ($-145.17 Mil) to Sep. 2023 ($-146.37 Mil) and declined from Sep. 2023 ($-146.37 Mil) to Dec. 2023 ($-147.10 Mil).

BioLargo's annual retained earnings declined from Dec. 2021 ($-139.12 Mil) to Dec. 2022 ($-143.59 Mil) and declined from Dec. 2022 ($-143.59 Mil) to Dec. 2023 ($-147.10 Mil).

BioLargo Retained Earnings Historical Data

The historical data trend for BioLargo's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Retained Earnings Chart

BioLargo Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-123.49

-132.04

-139.12

-143.59

-147.10

BioLargo Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-143.59	-143.84	-145.17	-146.37	-147.10

BioLargo Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BioLargo (OTCPK:BLGO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BioLargo (BioLargo) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

14921 Chestnut Street, Westminster, CA, USA, 92683

Website

https://www.biolargo.com

BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.

Executives

Linda Park	director	14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray	director	PO BOX 234, FREDERICK CO 80530
Jack B. Strommen	director	7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii	director	1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan	director	30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert	director, 10 percent owner, officer: Chief Executive Officer	3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc	10 percent owner	16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan	officer: Chief Financial Officer	8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano	director, officer: Corporate Secretary	3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc.	10 percent owner	2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code	10 percent owner	16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison	director
Eduardo Ruiz	director, 10 percent owner